-
J.
Bajaj,
Juan
Córdoba,
Kevin
Mullen,
Piero
Amodio,
Debbie
Shawcross,
R.
Butterworth,
Marsha
Morgan
(2011)
Review article: the design of clinical trials in hepatic encephalopathy – an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement
Alimentary Pharmacology & Therapeutics, 33
-
Douglas
Nguyen
(2012)
Falk Symposium 186 : Challenges of Liver Cirrhosis and Tumors : Prevent It , Treat It , Manage Consequences
-
C.
Stewart,
M.
Malinchoc,
W.
Kim,
P.
Kamath
(2007)
Hepatic encephalopathy as a predictor of survival in patients with end‐stage liver disease
Liver Transplantation, 13
-
P.
Kind,
G.
Hardman,
S.
Macran
(1999)
UK population norms for EQ-5D
-
C.
Bannister,
J.
Orr,
A.
Reynolds,
M.
Hudson,
P.
Conway,
A.
Radwan,
C.
Morgan,
C.
Currie
(2016)
Natural History of Patients Taking Rifaximin-α for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data.
Clinical therapeutics, 38 5
-
N.
Bass,
K.
Mullen,
A.
Sanyal,
F.
Poordad,
G.
Neff,
C.
Leevy,
S.
Sigal,
M.
Sheikh,
K.
Beavers,
Todd
Frederick,
L.
Teperman,
D.
Hillebrand,
Shirley
Huang,
K.
Merchant,
Audrey
Shaw,
E.
Bortey,
W.
Forbes
(2010)
Rifaximin treatment in hepatic encephalopathy.
The New England journal of medicine, 362 12
-
J.
Orr,
Craig
Currie,
E.
Berni,
A.
Goel,
Kieran
Moriarty,
Ashish
Sinha,
Fiona
Gordon,
A.
Dethier,
John
Dillon,
K.
Clark,
Paul
Richardson,
Paul
Middleton,
Vishal
Patel,
Debbie
Shawcross,
H.
Preedy,
R.
Aspinall,
M.
Hudson
(2016)
The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin‐α
Liver International, 36
-
G.
Cornah
(1974)
The department of health
Postgraduate Medical Journal, 50
-
M.
Nadim,
F.
Durand,
J.
Kellum,
J.
Levitsky,
J.
O’Leary,
C.
Karvellas,
J.
Bajaj,
A.
Davenport,
R.
Jalan,
P.
Angeli,
S.
Caldwell,
Javier
Fernández,
C.
Francoz,
G.
Garcia‐Tsao,
P.
Ginés,
M.
Ison,
D.
Kramer,
R.
Mehta,
R.
Moreau,
D.
Mulligan,
J.
Olson,
E.
Pomfret,
M.
Senzolo,
R.
Steadman,
R.
Subramanian,
J.
Vincent,
Y.
Genyk
(2016)
Management of the critically ill patient with cirrhosis: A multidisciplinary perspective.
Journal of hepatology, 64 3
-
(2016)
Cirrhosis in Over 16s: Assessment and Management. NICE guideline 50
-
J.
Bustamante,
A.
Rimola,
P.
Ventura,
M.
Navasa,
I.
Cirera,
Virginia
Reggiardo,
J.
Rodés
(1999)
Prognostic significance of hepatic encephalopathy in patients with cirrhosis.
Journal of hepatology, 30 5
-
J.
Orr,
Craig
Currie,
E.
Berni,
A.
Goel,
Kieran
Moriarty,
A.
Sinha,
F.
Gordon,
A.
Dethier,
John
Dillon,
K.
Clark,
P.
Richardson,
P.
Middleton,
V.
Patel,
D.
Shawcross,
H.
Preedy,
R.
Aspinall,
M.
Hudson,
Freeman
Road
(2016)
The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-
-
(2004)
World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, 2nd edn. Geneva: World Health Organization
-
B.
Sharma,
Praveen
Sharma,
A.
Agrawal,
S.
Sarin
(2009)
Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
Gastroenterology, 137 3
-
農林水産奨励会農林水産政策情報センター,
英国財務省
(2003)
The green book : appraisal and evaluation in central government
-
P.
Cochat,
L.
Vaucoret,
J.
Sarles
(2008)
Et al
Evidence Based Mental Health, 11
-
Kevin
Mullen,
Arun
Sanyal,
Nathan
Bass,
Fred
Poordad,
Muhammad
Sheikh,
R.
Frederick,
E.
Bortey,
W.
Forbes
(2014)
Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 12 8
-
Arun
Sanyal,
Z.
Younossi,
Nathan
Bass,
Kevin
Mullen,
Fred
Poordad,
Robert
Brown,
R.
Vemuru,
M.
Jamal,
Shirley
Huang,
K.
Merchant,
E.
Bortey,
W.
Forbes
(2011)
Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study
Alimentary Pharmacology & Therapeutics, 34
-
(2013)
The Real World Experience of Rifaximin in Hepatic Encephalopathy, Falk Found
-
G.
Bongaerts,
R.
Severijnen,
H.
Timmerman
(2005)
Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy.
Medical hypotheses, 64 1
-
Kavish
Patidar,
L.
Thacker,
J.
Wade,
R.
Sterling,
A.
Sanyal,
M.
Siddiqui,
S.
Matherly,
R.
Stravitz,
P.
Puri,
V.
Luketic,
M.
Fuchs,
M.
White,
N.
Noble,
A.
Unser,
H.
Gilles,
D.
Heuman,
J.
Bajaj
(2014)
Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization
The American Journal of Gastroenterology, 109
-
H.
Vilstrup,
P.
Amodio,
J.
Bajaj,
J.
Córdoba,
P.
Ferenci,
K.
Mullen,
K.
Weissenborn,
Philip
Wong,
J.
Talwalkar,
H.
Conjeevaram,
M.
Porayko,
R.
Merriman,
P.
Jansen,
F.
Zoulim
(2014)
Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.
Journal of hepatology, 61 3
-
P.
Amodio,
F.
Piccolo,
E.
Pettenò,
D.
Mapelli,
P.
Angeli,
Rosamaria
Iemmolo,
M.
Muraca,
C.
Musto,
G.
Gerunda,
C.
Rizzo,
C.
Merkel,
A.
Gatta
(2001)
Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients.
Journal of hepatology, 35 1
-
Emma
Baxter,
ChiMat
(2008)
NHS Atlas of Variation in Healthcare
-
Z.
Younossi,
G.
Guyatt,
M.
Kiwi,
N.
Boparai,
D.
King
(1999)
Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease
Gut, 45
-
A.
Goel,
N.
Patel,
R.
Blackwell,
S.
Crompton,
K.
Moriarty
(2014)
PWE-125 Rifaximin Treatment In Hepatic Encephalopathy (he) -– Marked Reduction In Hospital Admissions And Hospital Bed Day Occupancy In A District General Hospital
Gut, 63
-
N.
Timmins,
M.
Rawlins,
J.
Appleby,
Who
Thailand,
Hitap,
iDSI
(2017)
A Terrible Beauty: A short history of NICE the National Institute for Health and Care Excellence
F1000Research, 6
-
H
Aggan,
N
Farahat,
B.
Sabaa,
A
Elyamany,
R.
Esa
(2013)
PTU-110 Circulating Bone Marrow-Derived Stem Cells and Stem Cell Factor Serum Level in Chronic Hepatitis C: Relation to Hepatic Proliferation and Fibrosis
Gut, 62
-
Ananya
Das,
Radha
Dhiman,
V.
Saraswat,
Meera
Verma,
Subhash
Naik
(2001)
Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis
Journal of Gastroenterology and Hepatology, 16
-
R.
Fontana,
A.
Sanyal,
M.
Ghany,
William
Lee,
A.
Reid,
D.
Naishadham,
G.
Everson,
J.
Kahn,
A.
Bisceglie,
G.
Szabo,
T.
Morgan,
J.
Everhart,
J.
Bajaj,
C.
Schubert,
D.
Heuman,
J.
Wade,
D.
Gibson,
A.
Topaz,
K.
Saeian,
M.
Hafeezullah,
Debulon
Bell,
R.
Sterling,
R.
Stravitz,
V.
Luketic,
M.
White
(2010)
Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.
Gastroenterology, 138 7
-
(2015)
Meta-analysis of the impact of treatment with rifaximin-a on hospital resources in UK clinical practice DOF-XIFAX-006
-
E.
Berni,
C.
Bannister,
C.
Poole,
P.
Conway,
K.
Nanuwa,
C.
Currie
(2014)
PWE-154 The First Evaluation Of The Relationship Between The Chronic Liver Disease Questionnaire And The Eq-5d Index In Hepatic Encephalopathy Patients Treated With Rifaximin-a
Gut, 63
-
P.
Jepsen,
P.
Ott,
P.
Andersen,
H.
Sørensen,
H.
Vilstrup
(2010)
Clinical course of alcoholic liver cirrhosis: A Danish population‐based cohort study
Hepatology, 51